Zynerba Pharmaceuticals Company Profile (NASDAQ:ZYNE)

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals logoZynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain. The Company's ZYN002 is the synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear, odorless gel that is designed to provide controlled drug delivery with once- or twice-daily dosing. The Company's ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The transdermal patch is a non-invasive and non-oral dosage form of method of delivery. ZYN001 is a pro-drug, which is a drug administered in an inactive or less active form.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ZYNE
  • CUSIP:
Key Metrics:
  • Previous Close: $14.04
  • 50 Day Moving Average: $10.32
  • 200 Day Moving Average: $9.06
  • 52-Week Range: $4.64 - $21.56
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.65
  • P/E Growth: 0.00
  • Market Cap: $127.04M
  • Outstanding Shares: 9,199,000
Profitability:
  • Net Margins: -5,681.48%
  • Return on Equity: -51.49%
  • Return on Assets: -46.96%
Debt:
  • Current Ratio: 7.08%
  • Quick Ratio: 7.08%
Additional Links:
Companies Related to Zynerba Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Zynerba Pharmaceuticals (NASDAQ:ZYNE) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.60 (140.41% upside)

Analysts' Ratings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Show:
DateFirmActionRatingPrice TargetDetails
9/7/2016Canaccord GenuityReiterated RatingBuy$35.00View Rating Details
9/6/2016Roth CapitalSet Price TargetBuy$25.00View Rating Details
8/12/2016Piper Jaffray Cos.Reiterated RatingOverweight$42.00View Rating Details
6/28/2016Oppenheimer Holdings Inc.Reiterated RatingBuy$29.00View Rating Details
4/7/2016Jefferies GroupReiterated RatingBuy$32.00View Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016        
8/11/2016Q2($0.53)($0.70)ViewN/AView Earnings Details
5/12/2016Q1($0.56)($0.49)ViewN/AView Earnings Details
3/14/2016Q415($0.29)($0.62)ViewN/AView Earnings Details
11/11/2015Q3($0.41)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Current Year EPS Consensus Estimate: $-2.54 EPS
Next Year EPS Consensus Estimate: $-2.40 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.51)($0.43)($0.47)
Q2 20162($0.51)($0.48)($0.50)
Q3 20162($0.56)($0.54)($0.55)
Q4 20162($0.65)($0.54)($0.60)
Q1 20171($0.66)($0.66)($0.66)
Q2 20171($0.66)($0.66)($0.66)
Q3 20171($0.36)($0.36)($0.36)
Q4 20171($0.36)($0.36)($0.36)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Insider Ownership Percentage: 10.02%
Institutional Ownership Percentage: 23.78%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2016Suzanne M HanlonInsiderSell3,000$10.53$31,590.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
DateHeadline
prnewswire.com logoFighting Addiction and Other Unmet Medical Needs with Cannabidiol - PR Newswire (press release) (NASDAQ:ZYNE)
www.prnewswire.com - September 28 at 5:16 AM
4-traders.com logoZynerba Pharmaceuticals : Reports Inducement Grant to New Chief Financial Officer (NASDAQ:ZYNE)
www.4-traders.com - September 27 at 8:09 PM
News IconStock Noted Gapping Up Pre-Market: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Post News (NASDAQ:ZYNE)
www.kentuckypostnews.com - September 26 at 8:14 PM
benzinga.com logoGW Pharma's Epidiloex Data Is Good News For Zynerba - Benzinga (NASDAQ:ZYNE)
www.benzinga.com - September 26 at 8:14 PM
finance.yahoo.com logoGW Pharma's Epidiloex Data Is Good News For Zynerba (NASDAQ:ZYNE)
finance.yahoo.com - September 26 at 8:14 PM
News IconSell-side Taking Aim at Shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Frisco Fastball (NASDAQ:ZYNE)
friscofastball.com - September 25 at 7:03 PM
News IconAnalysts Take: Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Projected Earnings & Price Targets - Frisco Fastball (NASDAQ:ZYNE)
friscofastball.com - September 22 at 7:52 PM
News IconConsensus Analyst Opinions for: Nektar Therapeutics (NASDAQ:NKTR) , Zynerba Pharmaceuticals, Inc. (NASDAQ ... - Wall Street Times (press release) (NASDAQ:ZYNE)
www.wallstreetnews24.com - September 21 at 7:46 PM
News IconGreat Start Sours Midday (NASDAQ:ZYNE)
www.fxstreet.com - September 20 at 8:46 AM
fxpips.com logoBusiness Update: Companies Lifting the Stock Market Today (NASDAQ:ZYNE)
www.fxpips.com - September 20 at 8:46 AM
finance.yahoo.com logoGamida Cell Announces Appointment of Julian Adams, Ph.D. and Kenneth I. Moch to its Board of Directors (NASDAQ:ZYNE)
finance.yahoo.com - September 15 at 12:03 PM
News IconWhat is the Sell-side Saying About Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)? - Frisco Fastball (NASDAQ:ZYNE)
friscofastball.com - September 14 at 8:30 PM
News IconZynerba Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer - EconoTimes (NASDAQ:ZYNE)
www.econotimes.com - September 14 at 8:30 PM
publicnow.com logoZynerba Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer (NASDAQ:ZYNE)
www.publicnow.com - September 14 at 12:40 PM
News IconStock Under Consideration – Zynerba Pharmaceuticals, Inc ... - Wall Street Times (press release) (NASDAQ:ZYNE)
www.wallstreetnews24.com - September 12 at 7:41 PM
benzinga.com logoGW Pharmaceuticals Takeover Talk 'Seems A Bit Premature' (NASDAQ:ZYNE)
www.benzinga.com - September 9 at 7:51 PM
streetinsider.com logoForm 8-K Zynerba Pharmaceuticals, For: Sep 08 - StreetInsider.com (NASDAQ:ZYNE)
www.streetinsider.com - September 9 at 5:14 AM
News IconPlacing Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Shares Under the Microscope - Post News (NASDAQ:ZYNE)
www.kentuckypostnews.com - September 8 at 12:11 PM
benzinga.com logoGW Pharmaceuticals Takeover Talk 'Seems A Bit Premature' - Benzinga (NASDAQ:ZYNE)
www.benzinga.com - September 8 at 12:11 PM
News IconCanaccord Genuity Reiterates Buy at Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) - BNB Daily (blog) (NASDAQ:ZYNE)
www.baseball-news-blog.com - September 8 at 12:11 PM
nasdaq.com logoZynerba Pharmaceuticals to Participate in Upcoming Investor Conferences - Nasdaq (NASDAQ:ZYNE)
www.nasdaq.com - September 7 at 12:10 PM
publicnow.com logoZynerba Pharmaceuticals to Participate in Upcoming Investor Conferences (NASDAQ:ZYNE)
www.publicnow.com - September 6 at 8:22 PM
reuters.com logoBRIEF-Andersons names Anthony Lombardi as new chief information officer (NASDAQ:ZYNE)
www.reuters.com - September 3 at 5:10 AM
News IconShares Gapping Higher Pre-Market: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Post News (NASDAQ:ZYNE)
www.kentuckypostnews.com - September 2 at 8:03 PM
News IconStock in Review: Taking a Closer Look at Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Shares - Post News (NASDAQ:ZYNE)
www.kentuckypostnews.com - September 2 at 5:59 AM
reuters.com logoBRIEF-Zynerba Pharmaceuticals files for mixed shelf of up to $150 mln (NASDAQ:ZYNE)
www.reuters.com - September 1 at 8:14 PM
biz.yahoo.com logoZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an (NASDAQ:ZYNE)
biz.yahoo.com - September 1 at 8:14 PM
News IconGlobal Fibromyalgia Pipeline Landscape and Therapeutics Development Market H2 2016 (NASDAQ:ZYNE)
www.khq.com - August 30 at 11:42 AM
News IconWhat's Smoking In The Legal Pot? (NASDAQ:ZYNE)
www.finanzen.ch - August 29 at 8:22 PM
live-pr.com logoNewly released market study: Zynerba Pharmaceuticals, Inc. (ZYNE) - Financial and Strategic SWOT Analysis Review (NASDAQ:ZYNE)
www.live-pr.com - August 25 at 8:40 PM
News IconHow is the Crowd Rating Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Shares? - Post News (NASDAQ:ZYNE)
www.kentuckypostnews.com - August 25 at 5:12 AM
finance.yahoo.com logoZYNERBA PHARMACEUTICALS, INC. Financials (NASDAQ:ZYNE)
finance.yahoo.com - August 19 at 8:14 PM
News IconWhat is Wall Street Saying About Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)? - Post News (NASDAQ:ZYNE)
www.kentuckypostnews.com - August 18 at 8:38 PM
streetinsider.com logoForm 4 Zynerba Pharmaceuticals, For: Aug 05 Filed by: Hanlon Suzanne M. (NASDAQ:ZYNE)
www.streetinsider.com - August 17 at 8:45 PM
News IconZynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Is Executing On An Agressive Clinical Strategy (NASDAQ:ZYNE)
streetregister.com - August 17 at 11:26 AM
biz.yahoo.com logoZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors (NASDAQ:ZYNE)
biz.yahoo.com - August 16 at 11:48 AM
biz.yahoo.com logoZYNERBA PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:ZYNE)
biz.yahoo.com - August 11 at 9:04 PM
reuters.com logoBRIEF-Zynerba Pharmaceuticals reported Q2 EPS ($0.70) - Reuters (NASDAQ:ZYNE)
www.reuters.com - August 11 at 11:56 AM
sg.finance.yahoo.com logoZynerba reports 2Q loss (NASDAQ:ZYNE)
sg.finance.yahoo.com - August 11 at 11:56 AM
publicnow.com logoZynerba Pharmaceuticals Reports Second Quarter 2016 Financial Results and Organizational Changes (NASDAQ:ZYNE)
www.publicnow.com - August 11 at 11:56 AM
newsmaker.com.au logo2016 Pipeline of Alcohol Addiction Market Therapeutics Under Development Research (NASDAQ:ZYNE)
www.newsmaker.com.au - August 4 at 8:55 PM
nasdaq.com logoZynerba Pharmaceuticals to Present at Canaccord Genuity's 36th ... - Nasdaq (NASDAQ:ZYNE)
www.nasdaq.com - August 3 at 8:51 PM
finance.yahoo.com logoZynerba Pharmaceuticals to Present at Canaccord Genuity’s 36th Annual Growth Conference (NASDAQ:ZYNE)
finance.yahoo.com - August 3 at 11:46 AM
nasdaq.com logoZynerba Pharmaceuticals Announces Dosing of First Patients in Phase 2 STAR 1 Clinical Study of ZYN0 (NASDAQ:ZYNE)
www.nasdaq.com - August 2 at 5:22 AM
investors.com logoZynerba doses first patient in epilepsy gel trial (NASDAQ:ZYNE)
www.proactiveinvestors.com - August 1 at 8:11 PM
finance.yahoo.com logoZynerba Pharmaceuticals Announces Dosing of First Patients in Phase 2 STAR 1 Clinical Study of ZYN002 … (NASDAQ:ZYNE)
finance.yahoo.com - August 1 at 8:11 PM
News IconLearn details of the neuropathic pain pipeline products, key players involved and enlists all their major and minor projects (NASDAQ:ZYNE)
www.whatech.com - July 28 at 11:50 AM
News IconAre Analysts Bullish Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) After Last Week? - Press Telegraph (NASDAQ:ZYNE)
presstelegraph.com - July 23 at 9:31 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - TGP (NASDAQ:ZYNE)
telanaganapress.com - July 22 at 11:23 AM
News IconCan Zynerba Pharmaceuticals Inc's Tomorrow Be Different? The Stock Increases Again - Consumer Eagle (NASDAQ:ZYNE)
www.consumereagle.com - July 22 at 11:23 AM

Social

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff